From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

DeFronzo, 1988, Lilly Lecture: The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM, Diabetes, 37, 667, 10.2337/diab.37.6.667

Zimmet, 1978, The relationship of insulin response to a glucose stimulus over a wide range of glucose tolerance, Diabetologia, 15, 23, 10.1007/BF01219323

Saad, 1989, Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes, Lancet, i, 1356, 10.1016/S0140-6736(89)92804-3

Lillioja, 1988, Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians, N Engl J Med, 318, 1217, 10.1056/NEJM198805123181901

Warram, 1990, Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents, Ann Intern Med, 113, 909, 10.7326/0003-4819-113-12-909

Martin, 1992, Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study, Lancet, 340, 925, 10.1016/0140-6736(92)92814-V

Saad, 1988, The natural history of impaired glucose tolerance in the Pima Indians, N Engl J Med, 319, 1500, 10.1056/NEJM198812083192302

Jallut, 1990, Impaired glucose tolerance and diabetes in obesity: a 6 year follow-up study of glucose metabolism, Metabolism, 39, 1068, 10.1016/0026-0495(90)90168-C

Gulli, 1992, The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents, Diabetes, 41, 1575, 10.2337/diab.41.12.1575

Haffner, 1995, Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans, Diabetes, 44, 1386, 10.2337/diab.44.12.1386

Haffner, 1996, Insulin secretion and resistance in nondiabetic Mexican Americans and non-Hispanic whites with a parental history of diabetes, J Clin Endocrinol Metab, 81, 1846

Lillioja, 1993, Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus, N Engl J Med, 329, 1988, 10.1056/NEJM199312303292703

Dowse, 1996, Insulin levels and the natural history of glucose intolerance in Nauruans, Diabetes, 45, 1367, 10.2337/diab.45.10.1367

Lyssenko, 2005, Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes, Diabetes, 54, 166, 10.2337/diabetes.54.1.166

Weyer, 2001, Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development, Diabetes Care, 24, 89, 10.2337/diacare.24.1.89

Eriksson, 1989, Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus, N Engl J Med, 321, 337, 10.1056/NEJM198908103210601

DeFronzo, 1997, Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes, Diabetes Rev, 5, 177

DeFronzo, 2004, Pathogenesis of type 2 diabetes mellitus, Med Clin North Am, 88, 787, 10.1016/j.mcna.2004.04.013

Pendergrass, 2007, Muscle glucose transport and phosphorylation in type 2 diabetic, obese non-diabetic, and genetically predisposed individuals, Am J Physiol Endocrinol Metab, 292, E92, 10.1152/ajpendo.00617.2005

Groop, 2008, Genes and type 2 diabetes mellitus, Current Diab Reports, 8, 192, 10.1007/s11892-008-0033-y

Rothman, 1995, Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus, Proc Natl Acad Sci U S A, 92, 983, 10.1073/pnas.92.4.983

Pratipanawatr, 2001, Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated IRS-1 tyrosine phosphorylation, Diabetes, 50, 2572, 10.2337/diabetes.50.11.2572

Morino, 2005, Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents, J Clin Invest, 115, 3587, 10.1172/JCI25151

Kashyap, 2003, A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes, Diabetes, 52, 2461, 10.2337/diabetes.52.10.2461

DeFronzo, 1989, Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake, Metabolism, 38, 387, 10.1016/0026-0495(89)90129-7

Groop, 1989, Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus: evidence for multiple sites of insulin resistance, J Clin Invest, 84, 205, 10.1172/JCI114142

Ferrannini, 1988, The disposal of an oral glucose load in patients with non-insulin dependent diabetes, Metabolism, 37, 79, 10.1016/0026-0495(88)90033-9

DeFronzo, 1985, Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin-dependent (type II) diabetes mellitus, J Clin Invest, 76, 149, 10.1172/JCI111938

DeFronzo, 1979, Insulin sensitivity and insulin binding in maturity onset diabetes, J Clin Invest, 63, 939, 10.1172/JCI109394

James, 2008, The fundamental drivers of the obesity epidemic, Obesity Rev, 9, 6, 10.1111/j.1467-789X.2007.00432.x

DeFronzo, 1978, Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding, J Clin Invest, 62, 204, 10.1172/JCI109108

Koivisto, 1986, Physical training and insulin sensitivity, Diabetes Metab Rev, 1, 445, 10.1002/dmr.5610010407

Diamond, 1995, Reciprocal variation in insulin-stimulated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance, J Soc Gynecol Invest, 2, 708, 10.1177/107155769500200507

Bergman, 2002, The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes, Eur J Clin Invest, 32, 35, 10.1046/j.1365-2362.32.s3.5.x

Jallut, 1990, Impaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism, Metabolism, 39, 1068, 10.1016/0026-0495(90)90168-C

UK Prospective Diabetes Study (UKPDS) Group, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6

Levy, 1998, Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study, Diabet Med, 15, 290, 10.1002/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M

Abdul-Ghani, 2007, The relative contribution of insulin resistance and beta cell failure to the transition from normal to impaired glucose tolerance varies in different ethnic groups, Diabete Metab Synd, 1, 105, 10.1016/j.dsx.2007.02.004

Gastaldelli, 2004, Beta cell dysfunction and glucose intolerance: results from the San Antonio Metabolism (SAM) study, Diabetologia, 47, 31, 10.1007/s00125-003-1263-9

Ferrannini, 2005, Beta cell function in subjects spanning the range from normal glucose tolerance to overt diabetes mellitus: a new analysis, J Clin Endocrinol Metab, 90, 493, 10.1210/jc.2004-1133

Abdul-Ghani, 2006, Insulin secretion and insulin action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study (VAGES), Diabetes, 55, 1430, 10.2337/db05-1200

Abdul-Ghani, 2006, Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose, Diabetes Care, 29, 1130, 10.2337/dc05-2179

Ahren, 2003, Beta-cell function and insulin secretion, Ellenberg Rifkin's Diabetes Mellitus, p. 43

Reaven, 1989, Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance, Diabetologia, 32, 52, 10.1007/BF00265404

Bergman, 1989, Lilly Lecture: Toward physiological understanding of glucose tolerance: minimal-model approach, Diabetes, 38, 1512, 10.2337/diab.38.12.1512

American Diabetes Association, 2008, Diagnosis and classification of diabetes mellitus, Diabetes Care, 31, S55, 10.2337/dc08-S055

Butler, 2003, β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes, Diabetes, 52, 102, 10.2337/diabetes.52.1.102

Diabetes Prevention Program Research Group, 2007, The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program, Diabet Med, 24, 137, 10.1111/j.1464-5491.2007.02043.x

Nathan, 2006, Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy, Diabetes Care, 29, 1963, 10.2337/dc06-9912

Ziegler, 2008, Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3, Diabetes Care, 31, 464, 10.2337/dc07-1796

Smith, 2006, Lifestyle intervention for pre-diabetic neuropathy, Diabetes Care, 6, 415

Muller, 1996, Insulin response during the oral glucose tolerance test: the role of age, sex, body fat and the pattern of fat distribution, Aging, 8, 13

Rosenthal, 1982, Effect of age on glucose tolerance, insulin secretion, and in vivo insulin action, J Am Geriatrics Soc, 30, 562, 10.1111/j.1532-5415.1982.tb05662.x

Chang, 2003, Aging and insulin secretion, Am J Physiol Endocrinol Metab, 284, E7, 10.1152/ajpendo.00366.2002

Gautier, 2001, Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes, Diabetes, 50, 1828, 10.2337/diabetes.50.8.1828

Vauhkonen, 1997, Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. Metabolic studies on offspring of diabetic probands, J Clin Invest, 100, 86

Vaag, 1995, Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus, J Clin Invest, 95, 690, 10.1172/JCI117715

Barnett, 1981, Metabolic studies in unaffected co-twins of non-insulin-dependent diabetics, BMJ, 282, 1656, 10.1136/bmj.282.6277.1656

Watanabe, 1999, Familiarity of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus: Finland-United States Investigation of NIDDM Genes (FUSION) Study Investigators, Hum Hered, 39, 159, 10.1159/000022865

Grant, 2006, Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes, Nat Genet, 38, 320, 10.1038/ng1732

Helgason, 2007, Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution, Nat Genet, 39, 218, 10.1038/ng1960

Steinthorsdottir, 2007, A variant in CDKAL1 influences insulin response and risk of type 2 diabetes, Nat Genet, 39, 770, 10.1038/ng2043

Lyssenko, 2007, Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes, J Clin Invest, 117, 2155, 10.1172/JCI30706

Cauchi, 2006, Transcription factor TCF7L2 genetic study in the French population: expression in human β-cells and adipose tissue and strong association with type 2 diabetes, Diabetes, 55, 2903, 10.2337/db06-0474

Welters, 2008, Wnt signaling: relevance to β-cell biology and diabetes, Trends Endocrinol Metab, 19, 349, 10.1016/j.tem.2008.08.004

Unger, 1995, Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications, Diabetes, 44, 863, 10.2337/diab.44.8.863

Prentki, 2006, Islet beta cell failure in type 2 diabetes, J Clin Invest, 116, 1802, 10.1172/JCI29103

Kashyap, 2003, A sustained increase in plasma free fatty acids impairs insulin secretion in non-diabetic subjects genetically predisposed to develop type 2 diabetes, Diabetes, 52, 2461, 10.2337/diabetes.52.10.2461

Higa, 1999, Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats, Proc Natl Acad Sci U S A, 96, 11513, 10.1073/pnas.96.20.11513

Matsui, 2004, Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-γ–deficient mice on a high-fat diet, Diabetes, 53, 2844, 10.2337/diabetes.53.11.2844

Shimabukuro, 1998, Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats, J Biol Chem, 273, 3547, 10.1074/jbc.273.6.3547

Paolisso, 1998, Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes, Diabetologia, 41, 1127, 10.1007/s001250051041

Lupi, 2002, Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that β-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated, Diabetes, 51, 1437, 10.2337/diabetes.51.5.1437

Lupi, 2004, Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion, Am J Physiol Endocrinol Metab, 286, E560, 10.1152/ajpendo.00561.2002

Gastaldelli, 2007, Thiazolidinediones improve beta-cell function in type 2 diabetic patients, Am J Physiol Endocrinol Metab, 292, E871, 10.1152/ajpendo.00551.2006

Rossetti, 1990, Glucose toxicity (Review), Diabetes Care, 13, 610, 10.2337/diacare.13.6.610

Rossetti, 1987, Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats, J Clin Invest, 80, 1037, 10.1172/JCI113157

Patane, 2002, Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator–activated receptor-γ inhibition, Diabetes, 51, 2749, 10.2337/diabetes.51.9.2749

Andreozzi, 2004, Activation of the hexosamine pathway leads to phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin insulin biosynthetic pathway in RIN pancreatic beta-cells, Endocrinology, 145, 2845, 10.1210/en.2003-0939

Leahy, 1986, Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion: a study in normal rats using chronic in vivo glucose infusions, J Clin Invest, 77, 908, 10.1172/JCI112389

Leahy, 1987, Impaired insulin secretion associated with near normoglycemia: study in normal rats with 96-h in vivo glucose infusions, Diabetes, 36, 459, 10.2337/diab.36.4.459

Garvey, 1985, The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus, Diabetes, 34, 222, 10.2337/diab.34.3.222

Kosaka, 1980, Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment, Diabetologia, 18, 23, 10.1007/BF01228297

Andrews, 1984, Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal, Diabetes, 33, 634, 10.2337/diab.33.7.634

Eriksson, 1992, Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus, Diabetologia, 35, 291, 10.1007/BF00400933

Johnson, 1989, Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus, N Engl J Med, 321, 513, 10.1056/NEJM198908243210806

Ohsawa, 1989, Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets, Biochem Biophy Res Com, 160, 961, 10.1016/0006-291X(89)92529-1

Bretherton-Watt, 1989, Altered islet amyloid polypeptide (amylin) gene expression in rat models of diabetes, Diabetologia, 32, 881, 10.1007/BF00297454

Haataja, 2008, Islet amyloid in type 2 diabetes and the toxic oligomer hypothesis, Endocr Rev, 29, 303, 10.1210/er.2007-0037

Chavez, 2008, Physiological and molecular determinants of insulin action in the baboon, Diabetes, 57, 899, 10.2337/db07-0790

Mendoza, 2008, Fasting plasma glucose (FPG) and HbA1c predict quantitatively baboon pancreatic islet amyloidosis (PIA): a novel non-human primate model of β-cell failure in type 2 diabetes mellitus (T2DM) (Abstract), Diabetes, 57, A439

Cox, 2006, A second-generation genetic linkage map of the baboon (Papio hamadryas) genome, Genomics, 88, 274, 10.1016/j.ygeno.2006.03.020

Huang, 2007, High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated β-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes, Diabetes, 56, 2016, 10.2337/db07-0197

Ritzel, 2007, Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets, Diabetes, 56, 65, 10.2337/db06-0734

Hartter, 1991, Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans, Diabetologia, 34, 52, 10.1007/BF00404025

Lukinius, 1989, Co-localization of islet amyloid polypeptide and insulin in the beta cell secretory granules of the human pancreatic islets, Diabetologia, 32, 240, 10.1007/BF00285291

Lin, 2005, Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway, J Clin Endocrinol Metab, 90, 6678, 10.1210/jc.2005-0079

Drucker, 2006, The biology of incretin hormones, Cell Metab, 3, 153, 10.1016/j.cmet.2006.01.004

Drucker, 2006, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, Lancet, 368, 1696, 10.1016/S0140-6736(06)69705-5

Meier, 2006, Incretins and the development of type 2 diabetes, Curren Diab Reports, 6, 194, 10.1007/s11892-006-0034-7

Toft-Nielsen, 2001, Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients, J Clin Endocrinol Metab, 86, 3717, 10.1210/jcem.86.8.7750

Nauck, 1986, Reduced incretin effect in type 2 (non-insulin-dependent) diabetes, Diabetologia, 29, 46, 10.1007/BF02427280

Holst, 2006, Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005, Diabetologia, 49, 253, 10.1007/s00125-005-0107-1

Nauck, 1993, Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus, J Clin Invest, 91, 301, 10.1172/JCI116186

Meier, 2001, Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes, Diabetes, 50, 2497, 10.2337/diabetes.50.11.2497

Kjems, 2003, The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects, Diabetes, 52, 380, 10.2337/diabetes.52.2.380

Holst, 2004, Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans, Am J Physiol Endocrinol Metab, 287, E199, 10.1152/ajpendo.00545.2003

Jones, 1989, The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus, Diabetologia, 32, 668, 10.1007/BF00274255

Hojberg, 2009, Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes, Diabetologia, 52, 199, 10.1007/s00125-008-1195-5

DeFronzo, 2006, Regulation of intermediatory metabolism during fasting and refeeding. Chapter 52, Endocrinology, 1015

Shulman, 1985, Mechanism of liver glycogen repletion in vivo by nuclear magnetic resonance spectroscopy, J Clin Invest, 76, 1229, 10.1172/JCI112078

Firth, 1987, Insulin action in non-insulin-dependent diabetes mellitus: the relationship between hepatic and extrahepatic insulin resistance and obesity, Metabolism, 36, 1091, 10.1016/0026-0495(87)90031-X

Campbell, 1988, Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus, Metabolism, 37, 15, 10.1016/0026-0495(88)90023-6

Chen, 1988, Relationship between plasma glucose and insulin concentration, glucose production, and glucose disposal in normal subjects and patients with non-insulin-dependent diabetes, J Clin Invest, 82, 21, 10.1172/JCI113572

Jeng, 1994, Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM, Diabetes, 43, 1440, 10.2337/diab.43.12.1440

Henry, 1986, Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus, Diabetes, 35, 990, 10.2337/diab.35.9.990

DeFronzo, 1987, Regulation of hepatic glucose metabolism in humans, Diabetes Metab Rev, 3, 415, 10.1002/dmr.5610030204

Magnusson, 1992, Increased rate of gluconeogenesis in type II diabetes mellitus: a 13C nuclear magnetic resonance study, J Clin Invest, 90, 1323, 10.1172/JCI115997

Consoli, 1990, Mechanism of increased gluconeogenesis in noninsulin-dependent diabetes mellitus: role of alterations in systemic, hepatic, and muscle lactate and alanine metabolism, J Clin Invest, 86, 2038, 10.1172/JCI114940

Matsuda, 2002, Glucagon dose response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals, Metabolism, 51, 1111, 10.1053/meta.2002.34700

Unger, 1970, Studies of pancreatic α-cell function in normal and diabetic subjects, J Clin Invest, 49, 837, 10.1172/JCI106297

Baron, 1987, Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics, Diabetes, 36, 274, 10.2337/diab.36.3.274

Gastaldelli, 2000, Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study, Diabetes, 49, 1367, 10.2337/diabetes.49.8.1367

Clore, 2000, Glucose-6-phosphatase flux in vitro is increased in type 2 diabetes, Diabetes, 49, 969, 10.2337/diabetes.49.6.969

DeFronzo, 1979, The glucose clamp technique: a method for quantifying insulin secretion and resistance, Am J Physiol, 237, E214

Bajaj, 2003, Metabolic and molecular basis of insulin resistance, J Nuclear Cardiol, 10, 311, 10.1016/S1071-3581(03)00520-8

Reaven, 1988, Banting Lecture: Role of insulin resistance in human disease, Diabetes, 37, 595, 10.2337/diab.37.12.1595

Kolterman, 1981, Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus, J Clin Invest, 68, 957, 10.1172/JCI110350

Campbell, 1988, Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus, Metabolism, 37, 15, 10.1016/0026-0495(88)90023-6

Bogardus, 1984, Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects, J Clin Invest, 74, 1238, 10.1172/JCI111533

Butterfield, 1965, Peripheral glucose metabolism in control subjects and diabetic patients during glucose, glucose-insulin, and insulin sensitivity tests, Diabetologia, 1, 43, 10.1007/BF01338715

Zierler, 1963, Roles of insulin and growth hormone, based on studies of forearm metabolism in man, Medicine, 42, 385, 10.1097/00005792-196311000-00002

Bonadonna, 1996, Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM, Diabetes, 45, 915, 10.2337/diab.45.7.915

Rothman, 1992, 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate: evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus, J Clin Invest, 89, 1069, 10.1172/JCI115686

Cline, 1999, Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes, N Engl J Med, 341, 240, 10.1056/NEJM199907223410404

Mandarino, 1995, Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle, Am J Physiol, 269, E701

Vogt, 1998, Effects of insulin on subcellular localization of hexokinase II in human skeletal muscle in vivo, J Clin Endocrinol Metab, 83, 230

Mandarino, 1987, Effects of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase: evidence for their role in oxidative and nonoxidative glucose metabolism, J Clin Invest, 80, 655, 10.1172/JCI113118

Shulman, 1990, Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy, N Engl J Med, 322, 223, 10.1056/NEJM199001253220403

Groop, 1991, The role of free fatty acid metabolism in the pathogensis of insulin resistance in obesity and non-insulin dependent diabetes mellitus, J Clin Endocrinol Metab, 72, 96, 10.1210/jcem-72-1-96

Felber, 1987, Role of lipid oxidation in the pathogenesis of insulin resistance of obesity and type II diabetes, Diabetes, 36, 1341, 10.2337/diab.36.11.1341

Golay, 1988, Metabolic basis of obesity and non-insulin dependent diabetes mellitus, Diabetes/Metab Rev, 4, 727, 10.1002/dmr.5610040803

Cusi, 2000, Insulin resistance differentially affects the PI 3-kinase and MAP kinase-mediated signaling in human muscle, J Clin Invest, 105, 311, 10.1172/JCI7535

Saltiel, 2001, Insulin signalling and the regulation of glucose and lipid metabolism, Nature, 414, 799, 10.1038/414799a

Tanijuchi, 2006, Critical nodes in signaling pathways: insight into insulin action, Nat Rev Mol Cell Biol, 7, 85, 10.1038/nrm1837

Musi, 2006, Insulin resistance and improvements in signal transduction, Endocrine, 29, 73, 10.1385/ENDO:29:1:73

Kashyap, 2007, The insulin resistance syndrome: physiological considerations, Diabetes Vasc Dis Res, 4, 13, 10.3132/dvdr.2007.001

Kashyap, 2005, Insulin resistance is associated with impaired nitric oxide synthase (NOS) activity in skeletal muscle of type 2 diabetic subjects, J Clin Endocrinol Metab, 90, 1100, 10.1210/jc.2004-0745

Montagnani, 2001, Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179), J Biol Chem, 276, 30392, 10.1074/jbc.M103702200

Miyazaki, 2003, Rosiglitazone improves downstream insulin-receptor signaling in type 2 diabetic patients, Diabetes, 52, 1943, 10.2337/diabetes.52.8.1943

Kashyap, 2004, Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes, Am J Physiol Endocrinol Metab, 287, E537, 10.1152/ajpendo.00541.2003

Pratipanawatr, 2001, Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated IRS-1 tyrosine phosphorylation, Diabetes, 50, 2572, 10.2337/diabetes.50.11.2572

Krook, 2000, Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients, Diabetes, 49, 284, 10.2337/diabetes.49.2.284

Kim, 2002, Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects, Diabetes, 51, 443, 10.2337/diabetes.51.2.443

Hundal, 2002, Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes, J Clin Invest, 109, 1321, 10.1172/JCI0214955

Bouzakri, 2003, Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes, Diabetes, 52, 1319, 10.2337/diabetes.52.6.1319

Wang, 2004, Molecular mechanisms of insulin resistance that impact cardiovascular biology, Diabetes, 53, 2735, 10.2337/diabetes.53.11.2735

Draznin, 2006, Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85α: the two sides of a coin, Diabetes, 55, 2392, 10.2337/db06-0391

Hsueh, 1999, Insulin signaling in the arterial wall, Am J Cardiol, 84, 21J, 10.1016/S0002-9149(99)00353-7

Krook, 2000, Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients, Diabetes, 49, 284, 10.2337/diabetes.49.2.284

Hanley, 2002, Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study, Diabetes Care, 25, 1177, 10.2337/diacare.25.7.1177

Isomaa, 2001, Cardiovascular morbidity and mortality associated with the metabolic syndrome, Diabetes Care, 24, 683, 10.2337/diacare.24.4.683

Rutter, 2005, Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study, Diabetes, 54, 3252, 10.2337/diabetes.54.11.3252

Bonora, 2007, Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study, Diabetes Care, 30, 318, 10.2337/dc06-0919

Howard, 1998, Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the “minimal model”: Insulin Resistance Atherosclerosis Study (IRAS) Investigators, Ann Epidemiol, 8, 358, 10.1016/S1047-2797(98)00002-7

Bonora, 2002, HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study, Diabetes Care, 25, 1135, 10.2337/diacare.25.7.1135

Mazzone, 2006, Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial, JAMA, 296, 2572, 10.1001/jama.296.21.joc60158

Nissen, 2008, Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial, JAMA, 299, 1561, 10.1001/jama.299.13.1561

Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9

DeFronzo, 1978, Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange, Proc Natl Acad Sci U S A, 75, 5173, 10.1073/pnas.75.10.5173

DeFronzo, 1978, Lack of gastrointestinal mediator of insulin action in maturity onset diabetes, Lancet, 2, 1077, 10.1016/S0140-6736(78)91807-X

DeFronzo, 1983, Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia, Diabetes, 32, 35, 10.2337/diab.32.1.35

DeFronzo, 1985, Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin-dependent (type II) diabetes mellitus, J Clin Invest, 76, 149, 10.1172/JCI111938

Ferrannini, 1988, The disposal of an oral glucose load in patients with non-insulin dependent diabetes, Metabolism, 37, 79, 10.1016/0026-0495(88)90033-9

Bays, 2004, Role of the adipocytes, FFA, and ectopic fat in the pathogenesis of type 2 diabetes mellitus: PPAR agonists provide a rational therapeutic approach, J Clin Endocrinol Metab, 89, 463, 10.1210/jc.2003-030723

Bays, 2008, Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity, Expert Rev Cardio Ther, 6, 343, 10.1586/14779072.6.3.343

Bonadonna, 1991, Glucose metabolism in obesity and type 2 diabetes, Diabete Metab, 17, 112

DeFronzo, 2004, Dysfunctional fat cells, lipotoxicity, and type 2 diabetes, Int J Clin Pract Suppl, 143, 9, 10.1111/j.1368-504X.2004.00389.x

Fraze, 1985, Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance, J Clin Endocrinol Metab, 61, 807, 10.1210/jcem-61-5-807

Williamson, 1966, Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver, Proc Natl Acad Sci U S A, 56, 247, 10.1073/pnas.56.1.247

Bevilacqua, 1987, Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects, Metabolism, 36, 502, 10.1016/0026-0495(87)90051-5

Ferrannini, 1983, Effect of fatty acids on glucose production and utilization in man, J Clin Invest, 72, 1737, 10.1172/JCI111133

Thiebaud, 1982, Effect of long chain triglyceride infusion on glucose metabolism in man, Metabolism, 31, 1128, 10.1016/0026-0495(82)90163-9

Felber, 1964, Effects of fat infusion on glucose tolerance and insulin plasma levels, Int J Exp Med, 10, 153

Roden, 1996, Mechanism of free fatty acid-induced insulin resistance in humans, J Clin Invest, 97, 2859, 10.1172/JCI118742

Carpentier, 2000, Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes, Diabetes, 49, 399, 10.2337/diabetes.49.3.399

Salans, 1974, Glucose metabolism and the response to insulin by human adipose tissue in spontaneous and experimental obesity: effects of dietary composition and adipose cell size, J Clin Invest, 53, 848, 10.1172/JCI107625

Bray, 1977, Spontaneous and experimental human obesity: effects of diet and adipose cell size on lipolysis and lipogenesis, Metabolism, 26, 739, 10.1016/0026-0495(77)90061-0

Boden, 2002, Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction, Eur J Clin Invest, 32, 14, 10.1046/j.1365-2362.32.s3.3.x

Bajaj, 2002, Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes, Diabetes, 51, 3043, 10.2337/diabetes.51.10.3043

Richardson, 2005, Lipid infusion induces an inflammatory/fibrotic response and decreases expression of nuclear encoded mitochondrial genes in human skeletal muscle, J Biol Chem, 280, 10290, 10.1074/jbc.M408985200

Dresner, 1999, Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity, J Clin Invest, 103, 253, 10.1172/JCI5001

Griffin, 1999, Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade, Diabetes, 48, 1270, 10.2337/diabetes.48.6.1270

Itani, 2002, Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α, Diabetes, 51, 2005, 10.2337/diabetes.51.7.2005

Randle, 1963, The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus, Lancet, 1, 785, 10.1016/S0140-6736(63)91500-9

Mandarino, 1996, Interaction of carbohydrate and fat fuels in human skeletal muscle: impact of obesity and NIDDM, Am J Physiol, 270, E463

Kelley, 2000, Fuel selection in human skeletal muscle in insulin resistance: a reexamination, Diabetes, 49, 677, 10.2337/diabetes.49.5.677

Wititsuwannakul, 1977, Mechanism of palmityl coenzyme A inhibition of liver glycogen synthase, J Biol Chem, 252, 7812, 10.1016/S0021-9258(17)41039-8

Johnson, 1992, Effect of increased free fatty acid supply on glucose metabolism and skeletal muscle glycogen synthase activity in normal man, Clin Science, 82, 219, 10.1042/cs0820219

Pendergrass, 1998, In vivo glucose transport (GT) and phosphorylation (GP) in skeletal muscle are impaired by elevation of plasma FFA (Abstract), Diabetes, 47, A65

Belfort, 2005, Dose response effect of elevated plasma FFA on insulin signaling, Diabetes, 54, 1640, 10.2337/diabetes.54.6.1640

Petersen, 2005, Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents, Plos Med, 2, 879, 10.1371/journal.pmed.0020233

Yu, 2002, Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle, J Biol Chem, 277, 50230, 10.1074/jbc.M200958200

Ellis, 2000, Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle, Am J Physiol Endocrinol Metab, 279, E554, 10.1152/ajpendo.2000.279.3.E554

Coletta, Pioglitazone stimulates AMPK signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo, Diabetologia

Bajaj, 2005, Effect of sustained reduction in plasma free fatty acid concentration on intramuscular long chain-fatty acyl-CoAs and insulin action in patients with type 2 diabetes, Diabetes, 54, 3148, 10.2337/diabetes.54.11.3148

Attie, 2003, PGC-1alpha at the crossroads of type 2 diabetes, Nat Genet, 34, 244, 10.1038/ng0703-244

Puigserver, 2003, Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator, Endocrine Rev, 24, 78, 10.1210/er.2002-0012

Mootha, 2004, Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle, Proc Natl Acad Sci U S A, 101, 6570, 10.1073/pnas.0401401101

Wu, 1999, Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1, Cell, 98, 115, 10.1016/S0092-8674(00)80611-X

Montell, 2001, DAG accumulation from saturated fatty acids desensitizes insulin stimulation of glucose uptake in muscle cells, Am J Physiol Endocrinol Metab, 280, E229, 10.1152/ajpendo.2001.280.2.E229

Adams, 2004, Ceramide content is increased in skeletal muscle from obese insulin resistant humans, Diabetes, 53, 25, 10.2337/diabetes.53.1.25

Haus, 2009, Plasma ceramides are elevated in obese subjects with type 2 diabetes and are associated with the level of insulin resistance, Diabetes, 58, 337, 10.2337/db08-1228

Richardson, 2005, Lipid infusion induces an inflammatory/fibrotic response and decreases expression of nuclear encoded mitochondrial genes in human skeletal muscle, J Biol Chem, 280, 10290, 10.1074/jbc.M408985200

Patti, 2003, Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1, Proc Natl Acad Sci U S A, 100, 8466, 10.1073/pnas.1032913100

Mootha, 2003, PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes, Nat Genet, 34, 267, 10.1038/ng1180

Abdul-Ghani, 2008, Deleterious action of fatty acids on mitochondrial ATP synthsis: the link between lipotoxicity, mitochondrial dysfunction, and insulin resistance, Am J Physiol, 295, E678

Cervera, 2008, Mechanisms of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes, Am J Physiol Endocrinol Metab, 294, E846, 10.1152/ajpendo.00030.2008

Cervera, 2007, Improved splanchnic glucose metabolism is responsible for glycemic control in T2DM subjects treated with exenatide (Abstract), Diabetes, 56, A404

Edgerton, 2009, Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like peptide-1 infusion increases liver glucose uptake in the conscious dog, Diabetes, 58, 243, 10.2337/db08-0515

Ionut, 2008, Exenatide can reduce glucose independent of islet hormones or gastric emptying, Am J Physiol Endocrinol Metab, 295, E269, 10.1152/ajpendo.90222.2008

Reaven, 1987, Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus, J Clin Endocrinol Metab, 64, 106, 10.1210/jcem-64-1-106

Unger, 1970, Studies of pancreatic α-cell function in normal and diabetic subjects, J Clin Invest, 49, 837, 10.1172/JCI106297

Boden, 1983, Counterregulatory hormone release and glucose recovery after hypoglycemia in non-insulin-dependent diabetic patients, Diabetes, 32, 1055, 10.2337/diab.32.11.1055

Triplitt, 2006, Exenatide: first in class incretin mimetic for the treatment of type 2 diabetes mellitus, Expert Rev Endocrinol Metab, 1, 329, 10.1586/17446651.1.3.329

Petersen, 2001, Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans, Diabetologia, 44, 2018, 10.1007/s001250100006

DeFronzo, Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus, Endocrine Practice

Noonan, 2001, Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats, Life Sci, 68, 2967, 10.1016/S0024-3205(01)01090-6

Dominguez, 1994, Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats, Am J Physiol, 266, F283

Kamran, 1997, Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats, J Am Soc Nephol, 8, 943, 10.1681/ASN.V86943

Mogensen, 1971, Maximum tubular reabsorpiton capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects, Scan J Clin Lab Invest, 28, 101, 10.3109/00365517109090668

Rahmoune, 2005, Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non–insulin-dependent diabetes, Diabetes, 54, 3427, 10.2337/diabetes.54.12.3427

Hedley, 2004, Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002, JAMA, 291, 2847, 10.1001/jama.291.23.2847

Porte, 2006, Central regulation of energy homeostasis, Diabetes, 55, S155, 10.2337/db06-S019

Schwartz, 2000, Central nervous system control of food intake, Nature, 404, 661, 10.1038/35007534

Bruning, 2000, Role of brain insulin receptor in control of body weight and reproduction, Science, 289, 2122, 10.1126/science.289.5487.2122

Plum, 2006, Central insulin action in energy and glucose homeostasis, J Clin Invest, 116, 1761, 10.1172/JCI29063

Matsuda, 1999, Altered hypothalamic function in response to glucose ingestion in obese humans, Diabetes, 48, 1801, 10.2337/diabetes.48.9.1801

Obici, 2002, Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats, Nat Neurosci, 5, 566, 10.1038/nn0602-861

Obici, 2001, Central melanocortin receptors regulate insulin action, J Clin Invest, 108, 1079, 10.1172/JCI200112954

Cusi, 1996, Metabolic effects of metformin on glucose and lactate metabolism in NIDDM, J Clin Endocrinol Metab, 81, 4059

DeFronzo, 1995, Efficacy of metformin in patients with non-insulin dependent diabetes mellitus, N Engl J Med, 333, 541, 10.1056/NEJM199508313330902

Cusi, 1998, Metformin: a review of its metabolic effects, Diabetes Reviews, 6, 89

Miyazaki, 2001, Improved glycemic control and enhanced insulin sensitivity in liver and muscle in type 2 diabetic subjects treated with pioglitazone, Diabetes Care, 24, 710, 10.2337/diacare.24.4.710

Miyazaki, 2001, Effect of rosiglitazone on glucose and free fatty acid metabolism in type 2 diabetic patients, Diabetologia, 44, 2210, 10.1007/s001250100031

Miyazaki, 2002, Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients, J Clin Endocrinol Metab, 87, 2784, 10.1210/jcem.87.6.8567

Bajaj, 2004, Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type 2 diabetic patients, Internatl J Obesity, 28, 783, 10.1038/sj.ijo.0802625

Bajaj, 2005, Effects of PPARα and PPARγ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus, Diabetes, 54, 3148, 10.2337/diabetes.54.11.3148

Gastaldelli, 2006, The effect of pioglitazone on the liver, Diabetes Care, 29, 2275, 10.2337/dc05-2445

Gastaldelli, 2006, The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes, J Clin Endocrinol Metab, 91, 806, 10.1210/jc.2005-1159

Bajaj, 2007, Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus, Diabetologia, 50, 1723, 10.1007/s00125-007-0698-9

Miyazaki, 2008, Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients, Diabetes Obes Metab, 10, 1204, 10.1111/j.1463-1326.2008.00880.x

Natali, 2006, Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review, Diabetologia, 49, 434, 10.1007/s00125-006-0141-7

Kim, 2002, Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110-β protein levels in skeletal muscle of type 2 diabetic subjects, Diabetes, 51, 443, 10.2337/diabetes.51.2.443

Zhou, 2001, Role of AMP-activated protein kinase in mechanism of metformin action, J Clin Invest, 108, 1167, 10.1172/JCI13505

Musi, 2002, Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes, Diabetes, 51, 2074, 10.2337/diabetes.51.7.2074

Einhorn, 2000, Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group, Clin Ther, 22, 1395, 10.1016/S0149-2918(00)83039-8

Fonseca, 2000, Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial, JAMA, 283, 1695, 10.1001/jama.283.13.1695

Matthews, 2005, Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study, Diab/Metab Res Rev, 21, 167, 10.1002/dmrr.478

Charbonnel, 2005, Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes, Diabetologia, 48, 1093, 10.1007/s00125-005-1751-1

Inzucchi, 1998, Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus, N Engl J Med, 338, 867, 10.1056/NEJM199803263381303

Bajaj, 2004, Combination therapy in type 2 diabetes, International Textbook of Diabetes Mellitus, 3rd ed, p. 915, 10.1002/0470862092.d0613

Miyazaki, 2001, Effect of rosiglitazone on glucose and free fatty acid metabolism in type 2 diabetic patients, Diabetologia, 44, 2210, 10.1007/s001250100031

Miyazaki, 2002, Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients, J Clin Endocrinol Metab, 87, 2784, 10.1210/jcem.87.6.8567

Bajaj, 2003, Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes, Diabetes, 52, 1364, 10.2337/diabetes.52.6.1364

Belfort, 2006, A placebo controlled trial of pioglitazone in patients with non-alcoholic steatohepatitis, N Engl J Med, 355, 2297, 10.1056/NEJMoa060326

Yki-Jarvinen, 2004, Thiazolidinediones, N Engl J Med, 351, 1106, 10.1056/NEJMra041001

Kahn, 2006, Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy, N Engl J Med, 355, 2427, 10.1056/NEJMoa066224

Hanefeld, 2006, Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study, Cur Med Res Opinion, 22, 1211, 10.1185/030079906X112598

Tan, 2005, Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes, Diabetes Care, 28, 544, 10.2337/diacare.28.3.544

Rosenstock, 2006, Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (&gt;60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study, Diab Obes Metab, 8, 49, 10.1111/j.1463-1326.2005.00541.x

Home, 2007, Rosiglitazone RECORD study: glucose control outcomes at 18 months, Diabet Med, 24, 626, 10.1111/j.1464-5491.2007.02160.x

Bunck, One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial, Diabetes Care

DeFronzo, 2005, Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes, Diabetes Care, 28, 1092, 10.2337/diacare.28.5.1092

Klonoff, 2008, Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years, Curr Med Res Opin, 24, 275, 10.1185/030079908X253870

Johnson, 2002, Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes, Diabetes Care, 25, 2244, 10.2337/diacare.25.12.2244

Evans, 2006, Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin, Diabetologia, 49, 930, 10.1007/s00125-006-0176-9

UK Prospective Diabetes Study (UKPDS) Group, 1998, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UPKDS 34), Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8

Turner, 1999, Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group, JAMA, 281, 2005, 10.1001/jama.281.21.2005

U.K. Prospective Diabetes Diabetes Study Group, 1998, UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes, Diabetes Care, 21, 87, 10.2337/diacare.21.1.87

Wright, 2002, Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57), Diabetes Care, 25, 330, 10.2337/diacare.25.2.330

Matthews, 1998, UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group, Diabet Med, 15, 297, 10.1002/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.0.CO;2-W

U.K. prospective diabetes study 16, 1995, Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group, Diabetes, 44, 1249, 10.2337/diab.44.11.1249

Lupi, 1999, The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose, Eur J Pharmacol, 364, 205, 10.1016/S0014-2999(98)00807-3

Lupi, 2002, Lipotoxicity in human pancreatic islets and the protective effect of metformin, Diabetes, 51, S134, 10.2337/diabetes.51.2007.S134

Xiang, 2006, Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes, Diabetes, 55, 517, 10.2337/diabetes.55.02.06.db05-1066

2006, The Dream (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial, Lancet, 368, 1096, 10.1016/S0140-6736(06)69420-8

Knowler, 2005, Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program, Diabetes, 54, 1150, 10.2337/diabetes.54.4.1150

Buchanan, 2002, Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women, Diabetes, 51, 2796, 10.2337/diabetes.51.9.2796

DeFronzo

Lupi, 2004, Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion, Am J Physiol Endocrinol Metab, 286, E560, 10.1152/ajpendo.00561.2002

Finegood, 2001, β-Cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death, Diabetes, 50, 1021, 10.2337/diabetes.50.5.1021

Kim, 2002, Peroxisomal proliferator–activated receptor-γ upregulates glucokinase gene expression in β-cells, Diabetes, 51, 676, 10.2337/diabetes.51.3.676

Santini, 2004, Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells, Diabetes, 53, S79, 10.2337/diabetes.53.suppl_3.S79

Masuda, 1995, Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide, Diabetologia, 38, 24, 10.1007/BF02369349

Tourrel, 2001, Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age, Diabetes, 50, 1562, 10.2337/diabetes.50.7.1562

Kim, 2003, Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo, Diabetes, 52, 751, 10.2337/diabetes.52.3.751

Farilla, 2003, Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets, Endocrinology, 144, 5149, 10.1210/en.2003-0323

Ahren, 2005, Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year, Diabetes Care, 28, 1936, 10.2337/diacare.28.8.1936

Deacon, 2007, Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes, Expert Opin Invest Drugs, 16, 533, 10.1517/13543784.16.4.533

Balas, 2007, The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients, J Clin Endocrinol Metab, 92, 1249, 10.1210/jc.2006-1882

Riddle, 2003, The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients, Diabetes Care, 26, 3080, 10.2337/diacare.26.11.3080

Yki-Jarvinen, 1999, Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial, Ann Intern Med, 130, 389, 10.7326/0003-4819-130-5-199903020-00002

Holman, 2007, Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes, N Engl J Med, 357, 1716, 10.1056/NEJMoa075392

Henry, 1993, Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial, Diabetes Care, 16, 21, 10.2337/diacare.16.1.21

Heine, 2005, Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial, Ann Intern Med, 143, 559, 10.7326/0003-4819-143-8-200510180-00006

Barnett, 2007, Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial, Clin Thera, 29, 2333, 10.1016/j.clinthera.2007.11.006

Nauck, 2007, A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study, Diabetologia, 50, 259, 10.1007/s00125-006-0510-2

Nathan, 2009, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 32, 193, 10.2337/dc08-9025